Mediantechn (ALMDT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mediantechn (ALMDT) has a cash flow conversion efficiency ratio of 0.301x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.57 Million ≈ $-12.36 Million USD) by net assets (€-35.15 Million ≈ $-41.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Mediantechn to measure how many days the company can operate on defensive assets alone.
Mediantechn - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Mediantechn's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mediantechn Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mediantechn ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Exacompta Clairefontaine
PA:ALEXA
|
0.200x |
|
RF Industries Ltd
NASDAQ:RFIL
|
0.024x |
|
inTest Corporation
NYSE MKT:INTT
|
-0.010x |
|
GuocoLand (Malaysia) Bhd
KLSE:1503
|
-0.003x |
|
Li-FT Power Ltd.
F:WS0
|
-0.002x |
|
Associated Alcohols & Breweries Ltd.
NSE:ASALCBR
|
0.080x |
|
Osisko Metals Inc
V:OM
|
-0.019x |
|
INKEVERSE GROUP DL-001
F:5IK
|
N/A |
Annual Cash Flow Conversion Efficiency for Mediantechn (2013–2025)
The table below shows the annual cash flow conversion efficiency of Mediantechn from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see ALMDT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-35.15 Million ≈ $-41.10 Million |
€-17.43 Million ≈ $-20.37 Million |
0.496x | -6.18% |
| 2024-12-31 | €-33.97 Million ≈ $-39.71 Million |
€-17.95 Million ≈ $-20.98 Million |
0.528x | -73.12% |
| 2023-12-31 | €-10.29 Million ≈ $-12.03 Million |
€-20.24 Million ≈ $-23.66 Million |
1.966x | -9.71% |
| 2022-12-31 | €-7.25 Million ≈ $-8.48 Million |
€-15.79 Million ≈ $-18.46 Million |
2.177x | +206.22% |
| 2021-12-31 | €4.94 Million ≈ $5.77 Million |
€-10.12 Million ≈ $-11.84 Million |
-2.050x | -526.68% |
| 2020-12-31 | €-11.36 Million ≈ $-13.28 Million |
€-5.46 Million ≈ $-6.38 Million |
0.480x | +114.03% |
| 2019-12-31 | €1.28 Million ≈ $1.50 Million |
€-4.39 Million ≈ $-5.13 Million |
-3.424x | -99.00% |
| 2018-12-31 | €9.09 Million ≈ $10.63 Million |
€-15.64 Million ≈ $-18.29 Million |
-1.721x | -209.88% |
| 2017-12-31 | €24.94 Million ≈ $29.15 Million |
€-13.85 Million ≈ $-16.19 Million |
-0.555x | -184.16% |
| 2016-12-31 | €38.74 Million ≈ $45.29 Million |
€-7.57 Million ≈ $-8.85 Million |
-0.195x | -36.23% |
| 2015-12-31 | €26.24 Million ≈ $30.68 Million |
€-3.76 Million ≈ $-4.40 Million |
-0.143x | +41.99% |
| 2014-12-31 | €13.78 Million ≈ $16.11 Million |
€-3.41 Million ≈ $-3.98 Million |
-0.247x | -- |
| 2013-12-31 | €0.00 ≈ $0.00 |
€-4.42 Million ≈ $-5.16 Million |
x | -- |
About Mediantechn
Median Technologies SA engages in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development with operations spanning in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iSee for imaging services in clinical trials; eyonis for non-invasive diagnos… Read more